Form4insider filings, from the source

SEC Form 4 · accession 0001652917-15-000007

REGENERON PHARMACEUTICALS, INC. · REGN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Neil Stahl
Officer — EVP Research and Development
Period of report
Nov 5, 2015
Accepted (ET)
Nov 9, 2015 · 5:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockMay 28, 2015G1,000$0.00D16,405D
Common StockNov 5, 2015M75,000$30.63A97,029D
Common StockNov 5, 2015F4,047$567.63D92,982D
Common StockNov 5, 2015F39,605$567.63D53,377D
Common StockNov 5, 2015M25,000$21.25A78,377D
Common StockNov 5, 2015F935$567.63D77,442D
Common StockNov 5, 2015F13,312$567.63D64,130D
Common StockF1Nov 6, 2015S9,555$562.37D54,575D
Common StockF2Nov 6, 2015S8,345$563.43D46,230D
Common StockF3Nov 6, 2015S2,100$564.19D44,130D
Common StockF4Nov 9, 2015S9,694$558.37D34,436D
Common StockF5Nov 9, 2015S1,500$559.26D32,936D
Common StockF6Nov 9, 2015S3,900$560.31D29,036D
Common StockF7Nov 9, 2015S500$561.36D28,536D
Common StockF8Nov 9, 2015S5,607$562.31D22,929D
Common StockF9Nov 9, 2015S900$563.41D22,029D
Common Stockholding———14,376Iby GRAT
Common Stockholding———5,599IBy 401(k) Plan
Common Stockholding———10,000Iby GRAT

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Non-Qualified Stock Option (right to buy)F10$21.25Nov 5, 2015M25,000D—Dec 18, 2019Common Stock25,00020,295D
Non-Qualified Stock Option (right to buy)F11$30.63Nov 5, 2015M75,000D—Dec 14, 2020Common Stock75,00046,736D

Explanation of responses